Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2018 May 10;378(19):1789-1801.
doi: 10.1056/NEJMoa1802357. Epub 2018 Apr 15.

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M M Eggermont  1 , Christian U Blank  1 , Mario Mandala  1 , Georgina V Long  1 , Victoria Atkinson  1 , Stéphane Dalle  1 , Andrew Haydon  1 , Mikhail Lichinitser  1 , Adnan Khattak  1 , Matteo S Carlino  1 , Shahneen Sandhu  1 , James Larkin  1 , Susana Puig  1 , Paolo A Ascierto  1 , Piotr Rutkowski  1 , Dirk Schadendorf  1 , Rutger Koornstra  1 , Leonel Hernandez-Aya  1 , Michele Maio  1 , Alfonsus J M van den Eertwegh  1 , Jean-Jacques Grob  1 , Ralf Gutzmer  1 , Rahima Jamal  1 , Paul Lorigan  1 , Nageatte Ibrahim  1 , Sandrine Marreaud  1 , Alexander C J van Akkooi  1 , Stefan Suciu  1 , Caroline Robert  1
Affiliations
Free article
Clinical Trial

Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma

Alexander M M Eggermont et al. N Engl J Med. .
Free article

Abstract

Background: The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial to evaluate pembrolizumab as adjuvant therapy in patients with resected, high-risk stage III melanoma.

Methods: Patients with completely resected stage III melanoma were randomly assigned (with stratification according to cancer stage and geographic region) to receive 200 mg of pembrolizumab (514 patients) or placebo (505 patients) intravenously every 3 weeks for a total of 18 doses (approximately 1 year) or until disease recurrence or unacceptable toxic effects occurred. Recurrence-free survival in the overall intention-to-treat population and in the subgroup of patients with cancer that was positive for the PD-1 ligand (PD-L1) were the primary end points. Safety was also evaluated.

Results: At a median follow-up of 15 months, pembrolizumab was associated with significantly longer recurrence-free survival than placebo in the overall intention-to-treat population (1-year rate of recurrence-free survival, 75.4% [95% confidence interval {CI}, 71.3 to 78.9] vs. 61.0% [95% CI, 56.5 to 65.1]; hazard ratio for recurrence or death, 0.57; 98.4% CI, 0.43 to 0.74; P<0.001) and in the subgroup of 853 patients with PD-L1-positive tumors (1-year rate of recurrence-free survival, 77.1% [95% CI, 72.7 to 80.9] in the pembrolizumab group and 62.6% [95% CI, 57.7 to 67.0] in the placebo group; hazard ratio, 0.54; 95% CI, 0.42 to 0.69; P<0.001). Adverse events of grades 3 to 5 that were related to the trial regimen were reported in 14.7% of the patients in the pembrolizumab group and in 3.4% of patients in the placebo group. There was one treatment-related death due to myositis in the pembrolizumab group.

Conclusions: As adjuvant therapy for high-risk stage III melanoma, 200 mg of pembrolizumab administered every 3 weeks for up to 1 year resulted in significantly longer recurrence-free survival than placebo, with no new toxic effects identified. (Funded by Merck; ClinicalTrials.gov number, NCT02362594 ; EudraCT number, 2014-004944-37 .).

PubMed Disclaimer

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

MeSH terms

Associated data